📖
Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context
Halimatou Diawara, Jane Grant, Alassane Dicko, Seydou Traore, Djibrilla Issiaka, Fatoumata Koita, Mehreen Datoo, Mala Sylla, Abdrahmane Boncane Dicko, Issaka Sagara, Daniel Chandramohan, Adrian Vs Hill, Brian Greenwood, Jayne Webster

Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context

Science & Mathematics Published 2025 Verification Pending

Overview & Synopsis

Background The R21/Matrix-M malaria vaccine has been shown to provide high protective efficacy against malaria in a phase III trial, and has been recommended for use by WHO. The vaccine will soon be deployed at scale in sub-Saharan Africa. This study aimed to understand the caregiver and community acceptability of the R21/Matrix-M vaccine alongside existing malaria prevention interventions, according to the communities of participants in the seasonal R21/Matrix-M phase III trial in Mali. Methods Qualitative data were collected to assess the acceptability of the R21/Matrix-M vaccine alongside the three R21/Matrix-M or control vaccine priming injections given in the first year of the trial. A total of 33 in-depth interviews (IDIs), 12 focus group discussions (FGDs) and 45 exit interviews at the trial clinics were conducted with caregivers of trial participants, 18 IDIs and 8 FGDs were conducted with community members, 13 IDIs with community health workers and 8 IDIs with trial field staff. Data were coded using the constructs from Sekhon’s theoretical framework on acceptability. Results Acceptability of the R21/Matrix-M vaccine was driven mainly by the high burden of malaria in the highly seasonal study area and consequent demand for a malaria vaccine, a perceived high efficacy of the R21/Matrix-M vaccine, and a high level of trust and confidence in the trial and trial team. These perceptions of the acceptability of the R21/Matrix-M vaccine led to a reduced perceived importance of seasonal malaria chemoprevention (SMC) among some caregivers, while others viewed R21/Matrix-M, SMC and insecticide-treated nets as complementary. Conclusions The R21/Matrix-M vaccine was acceptable to caregivers and communities of participants in the R21/Matrix-M phase III trial in Mali. Implementation research is needed to evaluate and ensure co-coverage of complementary malaria control interventions, including SMC in seasonal settings, in the face of the scale-up of R21/Matrix-M and other malaria vaccines.

Indexed from repository: HAL Open Science (hal.science)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context
Author / Organization Halimatou Diawara, Jane Grant, Alassane Dicko, Seydou Traore, Djibrilla Issiaka, Fatoumata Koita, Mehreen Datoo, Mala Sylla, Abdrahmane Boncane Dicko, Issaka Sagara, Daniel Chandramohan, Adrian Vs Hill, Brian Greenwood, Jayne Webster
Subject & Discipline Multidisciplinary Academic Open Research
Categories Science & Mathematics
Publication Year 2025
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website HAL Open Science (hal.science)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-228677
Original Source Link Visit Source Page on hal.science »